ArticleBMC medicine2025
Multi-cancer early detection based on serum surface-enhanced Raman spectroscopy with deep learning: a large-scale case-control study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Accuracy of AI-based raman spectroscopy in the diagnosis of gastric cancer: a systematic review and meta-analysis.Lasers in medical science · 2026Pooled it
- Surface-Enhanced Raman Spectroscopy in Breast Cancer Detection: A Bibliometric Review and Landscape of Global Trends.Biosensors · 2026Review
- Multifunctional Nanomaterials for Precision Diagnostics and Drug Delivery: AI-Assisted Biosensing, Barrier-Directed Transport, Stimuli-Responsive Release, and Theranostic Integration.Molecules (Basel, Switzerland) · 2026Review
- Advanced integrated SERS-based strategies for the early diagnosis of upper gastrointestinal cancers.Journal of nanobiotechnology · 2026Review
- Article
- Gold- or Silver-Nanoparticle SERS Platforms for Plasma-Based Diagnostics and AI-Driven Analysis.Sensors (Basel, Switzerland) · 2026Review
- Recent Progress in Exosome-Derived Nanocarriers for Breast Cancer Therapy: Advances, Translational Barriers, and Scale-Up Considerations.Pharmaceutical research · 2026Review
- Raman Spectroscopy in Cancer Diagnostics and Surgery: 25 Years of Progress from Surface-Enhanced Raman Spectroscopy to Artificial Intelligence─A Bibliometric and Visualized Study.Analytical chemistry · 2026Review
- Machine Learning-Enabled Intelligent Analysis of Surface-Enhanced Raman Scattering: Methods, Applications, and Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Machine learning enhanced optical spectroscopy for breast cancer diagnosis: A review.Lasers in medical science · 2026Review
- A synthetic oversampling-based customized ResNet51-Conv1D framework for early colorectal cancer prediction using structured clinical data from the PLCO screening trial.BMC medical informatics and decision making · 2026Article
- DNAzyme-Based Nanostructures for Dynamic Cell Regulation and Sensing.ChemistryOpen · 2026Review
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.International journal of molecular sciences · 2026Review
- Label-free molecular profiling of cancer using Raman spectroscopy: from fundamentals to clinical applications.Frontiers in oncology · 2026Review
- Advanced Imaging for Live-Cell Spatiotemporal Monitoring: Technologies and Applications.Research (Washington, D.C.) · 2026Review
- AI-Assisted Detection of Early Gastric Cancer via Visualization of Mucosal Acidity Compromise During Endoscopy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Engineering Nanomaterials for Raman Bioimaging and Theranostics: Advances, Challenges, and Future Directions.ACS omega · 2025Review
- From Innovation to Application: Can Emerging Imaging Techniques Transform Breast Cancer Diagnosis?Diagnostics (Basel, Switzerland) · 2025Review
- Application of surface-enhanced Raman spectroscopy in the diagnosis and treatment of breast cancer.Frontiers in medicine · 2025Review
- Recent advances in applications of artificial intelligence-assisted Raman spectroscopy in diagnosis of cancers.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundEarly detection of cancer can help patients with more effective treatments and result in better prognosis. Unfortunately, established cancer screening technologies are limited for use, especially for multi-cancer early detection. In this study, we described a serum-based platform integrating surface-enhanced Raman spectroscopy (SERS) technology with resampling strategy, feature dimensionality enhancement, deep learning and interpretability analysis methods for sensitive and accurate pan-cancer screening.
methodsTotally, 1655 early-stage patients with breast cancer (BC, n = 569), lung cancer (LC, n = 513), thyroid cancer (TC, n = 220), colorectal cancer (CC, n = 215), gastric cancer (GC, n = 100), esophageal cancer (EC, n = 38), and 1896 healthy controls (HC) were enrolled. The serum SERS spectra were obtained from each participant. Data dimension enhancement was conducted by heatmap transformation and continuous wavelet transform (CWT). The dimensionalization SERS spectral data were subsequently analyzed by residual neural network (ResNet) as convolutional neural network (CNN) algorithm. Class activation mapping (CAM) method was performed to elucidate the potential biological significance of spectral data classification.
resultsAll participants were divided into a training set and a test set with a ratio of 7:3. The BorderlineSMOTE method was selected as the most appropriate resampling strategy and the deep neural network (DNN) model achieved desirable performance among all groups (accuracy rate: 93.15%, precision rate: 88:46%, recall rate: 85.68%, and F1-score: 86.98%), with the generated AUC values of 0.991 for HC, 0.995 for BC, 0.979 for LC, 0.996 for TC, 0.994 for CC, 0.982 for GC, and 0.941 for EC, respectively. Furthermore, the combination use of SERS spectra data and ResNet (form of heatmap) were also capable of effectively distinguishing different categories and making accurate predictions (accuracy rate: 94.75%, precision rate: 89.02, recall rate: 86.97, and F1-score: 87.88), with the AUC values of 0.996 for HC, 0.995 for BC, 0.988 for LC, 0.999 for TC, 0.993 for CC, 0.985 for GC, and 0.940 for EC, respectively. Additionally, strong wave number range of the spectral data was observed in the CAM analysis.
conclusionsOur study has offered a highly effective serum SERS-based approach for multi-cancer early detection, which might shed new light on cancer screening in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.